Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
Research ArticleBasic Science Investigations

Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT7 Receptor Neuroimaging: Toward the First PET Radiotracer

Laetitia Lemoine, Julien Andries, Didier Le Bars, Thierry Billard and Luc Zimmer
Journal of Nuclear Medicine November 2011, 52 (11) 1811-1818; DOI: https://doi.org/10.2967/jnumed.111.089185
Laetitia Lemoine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julien Andries
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Le Bars
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thierry Billard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luc Zimmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Brain serotonin 7 (5-hydroxytryptamine 7, or 5-HT7) is the most recently identified serotonin receptor. It is involved in mood disorders and is studied as a target for antidepressants. Because no radioligand has yet been successfully used to study this receptor by PET neuroimaging, the objective of the present study was to develop a 5-HT7 18F-labeled radiotracer. Methods: Four structural analogs of SB269970, a specific 5-HT7 receptor antagonist, were synthesized. The nitro precursors of these analogs were radiolabeled by 18F nucleophilic substitution. Analog antagonist effects were investigated by cellular functional assay. The cerebral distribution of radiolabeled molecules was studied by in vitro autoradiography in rats, and respective selectivity was determined by competition with the 5-HT7 receptor antagonist SB269970 at different concentrations. Ex vivo small-animal PET studies in rats and in vivo PET studies in cats focused on the 1-(2-{(2R)-1-[(fluorophenyl)sulfonyl]pyrrolidin-2-yl}ethyl)-4-methylpiperidine (FP3) series. Results: Four analogs were synthesized from the SB269970 pharmacophore and divided into an FP3 (18F-4FP3 and 18F-2FP3) and an 1-(2-{(2R)-1-[(fluorophenyl)sulfonyl]pyrrolidin-2-yl}ethyl)-4-(2-methoxyphenyl)piperazine (FPMP) (18F-2FPMP and 18F-4FPMP) series. The chemical and radiochemical purities of the 4 radiolabeled molecules were greater than 98%. All presented suitable affinity for 5-HT7 (apparent dissociation constant [KD] between 1.6 and 14 nM), although the FPMP series showed moderate agonist activity for 5-HT1A receptors. Lipophilicity values were predictive of good radiotracer blood–brain barrier penetration (logD from 1.4 to 3.9). In vitro competition with a 5-HT7 antagonist, SB269970, revealed that only radioligands from the FP3 series were displaced by the 5-HT7–specific antagonist: subsequent in vivo study, therefore, focused on this series. Ex vivo 18F-4FP3 and 18F-2FP3 autoradiography was in accordance with the 5-HT7 brain distribution, with few brain radioactive metabolites. PET scans in cats showed that pretreatment with a 5-HT7 antagonist significantly reduced 18F-2FP3 but not 18F-4FP3 binding. Conclusion: The 4 PET radiotracers had suitable characteristics for 5-HT7 receptor probing in vitro, although the FP3 series seemed to be more specific for in vivo imaging of 5-HT7 receptors. In particular, on the basis of the in vivo results, 18F-2FP3 appears to be the first PET radiotracer to enable in vivo imaging of 5-HT7 receptors in animal models, possibly leading to neuroimaging studies in humans.

  • PET
  • tracer development
  • 5-HT7 receptors
  • rat
  • cat

Footnotes

  • Published online Oct. 11, 2011.

  • © 2011 by Society of Nuclear Medicine
View Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 52 (11)
Journal of Nuclear Medicine
Vol. 52, Issue 11
November 1, 2011
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT7 Receptor Neuroimaging: Toward the First PET Radiotracer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT7 Receptor Neuroimaging: Toward the First PET Radiotracer
Laetitia Lemoine, Julien Andries, Didier Le Bars, Thierry Billard, Luc Zimmer
Journal of Nuclear Medicine Nov 2011, 52 (11) 1811-1818; DOI: 10.2967/jnumed.111.089185

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Comparison of 4 Radiolabeled Antagonists for Serotonin 5-HT7 Receptor Neuroimaging: Toward the First PET Radiotracer
Laetitia Lemoine, Julien Andries, Didier Le Bars, Thierry Billard, Luc Zimmer
Journal of Nuclear Medicine Nov 2011, 52 (11) 1811-1818; DOI: 10.2967/jnumed.111.089185
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Radiosynthesis and In Vivo Evaluation of Novel Radioligands for PET Imaging of Cerebral 5-HT7 Receptors
  • Google Scholar

More in this TOC Section

  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
  • Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy
  • Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire